USPTO serial 79347617
INVOX
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Mar 26, 2024
- Examiner
- BERNS, LEE ANNE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with INVOX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Catherine J. Holland
Catherine J. Holland Knobbe, Martens, Olson & Bear, LLP2040 Main Street, 14th FloorIrvine, CA 92614UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceuticals for use in oncology, cardio-respiratory, haematology and immunity, paediatric and regenerative medicine; Pharmaceutical preparations and substances for oncology, cardio-respiratory, haematology and immunity, paediatric and regenerative medicine and for the prevention and treatment of inflammation and infectious diseases; chemical preparations for pharmaceutical purposes, namely, for use in oncology, cardio-respiratory, haematology and immunity, paediatric and regenerative medicine and for the treatment of inflammation and infectious diseases; chemical reagents for medical use; biotechnological preparations for medical use for use in oncology, cardio-respiratory, haematology and immunity, paediatric and regenerative medicine and for the treatment of inflammation and infectious diseases; biological adjuvants for medical purposes; biochemical preparations for medical use for use in oncology, cardio-respiratory, haematology and immunity, paediatric and regenerative medicine and for the treatment of inflammation and infectious diseases; preparations for deodorizing air; medicated deodorants for health and medical purposes; oils for medical purposes; air purifying preparations, pharmaceutical preparations for inhalers; none of the aforesaid goods being disinfectants or sanitary preparations, and not being adapted for use as disinfectant or sanitisers; none of the aforesaid being goods for use in diagnostics or for use in the examination, processing, transportation or testing of veterinary or medical samples | ACTIVE | — |
| 010 | Surgical instruments and apparatus, and medical devices, namely, inhalation devices in the field of drug delivery systems, excluding medical and veterinary sample containers, processing and analysis machines and test kits and personal protective equipment (PPE); inhalers for medical and pharmaceutical purposes; none of the aforesaid being goods for use in the examination, processing, transportation or testing of veterinary or medical samples or for use in diagnostics or in laboratory automation for diagnostic purposes, sample handling or sample preparation enabling and/or supporting medical, patient and veterinary data testing, processing and/or analysis | ACTIVE | — |
| 036 | Financing and equity investment services in the fields of pharmaceuticals, biotechnology life sciences; capital financing services in the fields of pharmaceuticals, biotechnology, life sciences; making direct and indirect investments, namely providing venture capital, private equity and investment funding for the development and commercialization of products and management of product portfolios in the fields of pharmaceuticals, biotechnology, life sciences; investment services, namely, asset and investment acquisition, and development services; none of the aforesaid services being in relation to the examination, processing, transportation or testing services relating to veterinary or medical samples; none of the aforesaid services being in relation to diagnostic applications by means of medical samples or in the field of laboratory automation for diagnostic purposes by means of medical samples, specimen handling or sample preparation or being in the field of software and IT services for enabling and/or supporting medical, patient and veterinary sample data testing, processing and/or analysis | ACTIVE | — |
| 042 | Pharmaceutical research and development in the field of biotechnology, medical devices in the field of drug delivery systems; scientific research for clinical, medical and pharmaceutical purposes in the field of biotechnology, medical devices for drug delivery systems and life sciences; scientific research and development in the field of biotechnology medical devices, life sciences and healthcare technology; pharmaceutical products development and medical device product development in the field of biotechnology, medical devices for drug delivery systems and life sciences; none of the aforesaid being in relation to the examination, processing, transportation or testing services relating to veterinary; none of the aforesaid services being in relation to diagnostic applications by means of medical samples or in the field of laboratory automation for diagnostic purposes by means of medical samples, specimen handling or sample preparation or being in the field of software and IT services for enabling and/or supporting medical, patient and veterinary sample data testing, processing and/or analysis | ACTIVE | — |
| 045 | Licensing of intellectual property rights; licensing of intellectual property in the field of pharmaceutical, biotechnology, life sciences; none of the aforesaid being in relation to the examination, processing, transportation or testing services relating to veterinary or medical samples; none of the aforesaid services being in relation to diagnostic applications by means of medical samples or in the field of laboratory automation for diagnostic purposes by means of medical samples, specimen handling or sample preparation or being in the field of software and IT services for enabling and/or supporting medical, patient and veterinary sample data testing, processing and/or analysis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by invoX Pharma Limited
- Other trademarks owned by invoX Pharma Limited
- Other trademarks owned by invoX Pharma Limited
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 036
- Other trademarks in Class 042
- Other trademarks in Class 045
- Similar marks named INVOX
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 18, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 23, 2026 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 30, 2025 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Nov 23, 2024 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Nov 5, 2024 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Oct 7, 2024 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jun 27, 2024 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 26, 2024 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Mar 26, 2024 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 13, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 24, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 24, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Jan 9, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 9, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 8, 2024 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Dec 20, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 20, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Dec 20, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 5, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 7, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 6, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 6, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 24, 2023 | LIME | LIMITATION FROM THE IB - REQUEST EXAM REVIEW | — |
| Jul 30, 2023 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| May 24, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| May 4, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| May 4, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 16, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 15, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 14, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 23, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 19, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 18, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |